Please try another search
For the nine months ended 30 September 2013, GeneLink Inc. revenues decreased 32% to $1.2M. Net loss decreased 40% to $1.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Selling, general and administrative decrease of 42% to $1.6M (expense), Research and development decrease of 56% to $67K (expense).
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 |
---|---|---|---|---|
Total Revenue | 0.29 | 0.87 | 0.4 | 0.41 |
Gross Profit | 0.07 | 0.25 | 0.09 | -0.02 |
Operating Income | -0.6 | -0.66 | -0.27 | -0.95 |
Net Income | -0.54 | -0.68 | -0.35 | -1.01 |
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 |
---|---|---|---|---|
Total Assets | 1.28 | 1.27 | 1.24 | 1.45 |
Total Liabilities | 4.49 | 4.37 | 4.25 | 4.12 |
Total Equity | -3.2 | -3.09 | -3.02 | -2.66 |
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.37 | -0.3 | -0.15 | -2.38 |
Cash From Investing Activities | 0 | 0 | 0 | 0.3 |
Cash From Financing Activities | 0.34 | 0.14 | 1.5 | |
Net Change in Cash | -0.03 | -0.16 | -0.15 | -0.58 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review